Key Highlights • Leadership team in place: Following appointment as Nigel Lange as CEO, key recent hires include a Chief Medical Officer, Head of Medical Affairs, Director of Access Reimbursement, Economics and Assessment and Director of Clinical development • Finalising data package for HDE submission: Currently finalising an updated dataset which involves a more recent data cut-off point, to support its HDE application to the FDA • Targeting hospitals in Greater London in the near-term: Pushing forward with launch preparation activities throughout Europe including establishing the Osprey registry • Additional sales in New Zealand: Following OncoSil’s first ever commercial sale, OncoSil has achieved further sales in New Zealand • Cash position: Cash balance of $15.3 million as at 31 March 2021
OSL Price at posting:
9.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)